Gliadin nanoparticles for the controlled release of all- trans-retinoic acid

The general objective of this work was to study the feasibility of preparing small-sized carriers from vegetal macromolecules. For this purpose, gliadin (a vegetal protein fraction from wheat gluten) nanoparticles were chosen as drug carriers for all-trans-retinoic acid (RA). The systems were prepar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 1996-04, Vol.131 (2), p.191-200
Hauptverfasser: Ezpeleta, Isabel, Irache, Juan M., Stainmesse, Serge, Chabenat, Christiane, Gueguen, Jacques, Popineau, Yves, Orecchioni, Anne-Marie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 200
container_issue 2
container_start_page 191
container_title International journal of pharmaceutics
container_volume 131
creator Ezpeleta, Isabel
Irache, Juan M.
Stainmesse, Serge
Chabenat, Christiane
Gueguen, Jacques
Popineau, Yves
Orecchioni, Anne-Marie
description The general objective of this work was to study the feasibility of preparing small-sized carriers from vegetal macromolecules. For this purpose, gliadin (a vegetal protein fraction from wheat gluten) nanoparticles were chosen as drug carriers for all-trans-retinoic acid (RA). The systems were prepared by a desolvation method for macro-molecules, which enabled us to obtain gliadin nanoparticles of about 500 nm, with a yield close to 90% of the initial protein. All experiments were performed using environmentally acceptable solvents such as ethanol and water. Moreover, due to the low solubility of this protein in water and to its high hydrophobicity, nanoparticles from gliadin do not need any further chemical or physical treatment to harden them. Gliadin nanoparticles were quite stable over 4 days in phosphate-buffered saline (PBS), but were degraded rapidly over 3 h when incubated in PBS solution containing trypsin. However, chemical cross-linkage of nanoparticles with glutaraldehyde significantly increased their stability. Under our experimental conditions, the payload limit was 76.4 μg RA/mg nanoparticles (for an RA/initial protein ratio of 90 μg/mg), which corresponded to a RA entrapment efficiency of about 75% of added drug. Nevertheless, the entrapment efficiency was high (between 97 and 85%) for RA/initial protein ratios up to 90 μg/mg. Finally, the in vitro release profiles of RA-loaded gliadin nanoparticles showed a biphasic pattern. An initial burst effect (in which about 20% RA was released) followed by zero-order diffusion (release rate 0.065 mg RA/h) were observed.
doi_str_mv 10.1016/0378-5173(95)04338-1
format Article
fullrecord <record><control><sourceid>elsevier_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02699143v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0378517395043381</els_id><sourcerecordid>0378517395043381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-526c398248775aeee5678000484ee5e810d47522efec4f787b1c09abf2f134793</originalsourceid><addsrcrecordid>eNp9kE9LAzEQxYMoWKvfwEMOHuwhmn-7yV6EUrQVFrzoOaTZCY3ETUmWgt_eXSs9epph-L2ZeQ-hW0YfGGX1IxVKk4opcd9UCyqF0ISdoRnTShAhVX2OZifkEl2V8kkprTkTM9SuY7Bd6HFv-7S3eQguQsE-ZTzsALvUDznFCB3OEMEWwMljGyPBQ7Z9IRmG0KfgsHWhu0YX3sYCN391jj5ent9XG9K-rV9Xy5a48beBVLx2otFcaqUqCwBVrfT4kdRy7EEz2klVcQ4enPRKqy1ztLFbzz0b7TRijhbHvTsbzT6HL5u_TbLBbJatmWaU103DpDiwkZVH1uVUSgZ_EjBqpvTMFI2ZojFNZX7TM5Ps7ijb2-Js9KNZF8pJK6hSilcj9nTEYLR7CJBNcQF6B13I4AbTpfD_nR83A4GP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Gliadin nanoparticles for the controlled release of all- trans-retinoic acid</title><source>Elsevier ScienceDirect Journals</source><creator>Ezpeleta, Isabel ; Irache, Juan M. ; Stainmesse, Serge ; Chabenat, Christiane ; Gueguen, Jacques ; Popineau, Yves ; Orecchioni, Anne-Marie</creator><creatorcontrib>Ezpeleta, Isabel ; Irache, Juan M. ; Stainmesse, Serge ; Chabenat, Christiane ; Gueguen, Jacques ; Popineau, Yves ; Orecchioni, Anne-Marie</creatorcontrib><description>The general objective of this work was to study the feasibility of preparing small-sized carriers from vegetal macromolecules. For this purpose, gliadin (a vegetal protein fraction from wheat gluten) nanoparticles were chosen as drug carriers for all-trans-retinoic acid (RA). The systems were prepared by a desolvation method for macro-molecules, which enabled us to obtain gliadin nanoparticles of about 500 nm, with a yield close to 90% of the initial protein. All experiments were performed using environmentally acceptable solvents such as ethanol and water. Moreover, due to the low solubility of this protein in water and to its high hydrophobicity, nanoparticles from gliadin do not need any further chemical or physical treatment to harden them. Gliadin nanoparticles were quite stable over 4 days in phosphate-buffered saline (PBS), but were degraded rapidly over 3 h when incubated in PBS solution containing trypsin. However, chemical cross-linkage of nanoparticles with glutaraldehyde significantly increased their stability. Under our experimental conditions, the payload limit was 76.4 μg RA/mg nanoparticles (for an RA/initial protein ratio of 90 μg/mg), which corresponded to a RA entrapment efficiency of about 75% of added drug. Nevertheless, the entrapment efficiency was high (between 97 and 85%) for RA/initial protein ratios up to 90 μg/mg. Finally, the in vitro release profiles of RA-loaded gliadin nanoparticles showed a biphasic pattern. An initial burst effect (in which about 20% RA was released) followed by zero-order diffusion (release rate 0.065 mg RA/h) were observed.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/0378-5173(95)04338-1</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>All- trans-retinoic acid ; Biological and medical sciences ; Controlled release ; Cross-linking ; Desolvation ; General pharmacology ; Gliadin ; Life Sciences ; Medical sciences ; Nanoparticle ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments</subject><ispartof>International journal of pharmaceutics, 1996-04, Vol.131 (2), p.191-200</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-526c398248775aeee5678000484ee5e810d47522efec4f787b1c09abf2f134793</citedby><cites>FETCH-LOGICAL-c433t-526c398248775aeee5678000484ee5e810d47522efec4f787b1c09abf2f134793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0378517395043381$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3077725$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.inrae.fr/hal-02699143$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ezpeleta, Isabel</creatorcontrib><creatorcontrib>Irache, Juan M.</creatorcontrib><creatorcontrib>Stainmesse, Serge</creatorcontrib><creatorcontrib>Chabenat, Christiane</creatorcontrib><creatorcontrib>Gueguen, Jacques</creatorcontrib><creatorcontrib>Popineau, Yves</creatorcontrib><creatorcontrib>Orecchioni, Anne-Marie</creatorcontrib><title>Gliadin nanoparticles for the controlled release of all- trans-retinoic acid</title><title>International journal of pharmaceutics</title><description>The general objective of this work was to study the feasibility of preparing small-sized carriers from vegetal macromolecules. For this purpose, gliadin (a vegetal protein fraction from wheat gluten) nanoparticles were chosen as drug carriers for all-trans-retinoic acid (RA). The systems were prepared by a desolvation method for macro-molecules, which enabled us to obtain gliadin nanoparticles of about 500 nm, with a yield close to 90% of the initial protein. All experiments were performed using environmentally acceptable solvents such as ethanol and water. Moreover, due to the low solubility of this protein in water and to its high hydrophobicity, nanoparticles from gliadin do not need any further chemical or physical treatment to harden them. Gliadin nanoparticles were quite stable over 4 days in phosphate-buffered saline (PBS), but were degraded rapidly over 3 h when incubated in PBS solution containing trypsin. However, chemical cross-linkage of nanoparticles with glutaraldehyde significantly increased their stability. Under our experimental conditions, the payload limit was 76.4 μg RA/mg nanoparticles (for an RA/initial protein ratio of 90 μg/mg), which corresponded to a RA entrapment efficiency of about 75% of added drug. Nevertheless, the entrapment efficiency was high (between 97 and 85%) for RA/initial protein ratios up to 90 μg/mg. Finally, the in vitro release profiles of RA-loaded gliadin nanoparticles showed a biphasic pattern. An initial burst effect (in which about 20% RA was released) followed by zero-order diffusion (release rate 0.065 mg RA/h) were observed.</description><subject>All- trans-retinoic acid</subject><subject>Biological and medical sciences</subject><subject>Controlled release</subject><subject>Cross-linking</subject><subject>Desolvation</subject><subject>General pharmacology</subject><subject>Gliadin</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Nanoparticle</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LAzEQxYMoWKvfwEMOHuwhmn-7yV6EUrQVFrzoOaTZCY3ETUmWgt_eXSs9epph-L2ZeQ-hW0YfGGX1IxVKk4opcd9UCyqF0ISdoRnTShAhVX2OZifkEl2V8kkprTkTM9SuY7Bd6HFv-7S3eQguQsE-ZTzsALvUDznFCB3OEMEWwMljGyPBQ7Z9IRmG0KfgsHWhu0YX3sYCN391jj5ent9XG9K-rV9Xy5a48beBVLx2otFcaqUqCwBVrfT4kdRy7EEz2klVcQ4enPRKqy1ztLFbzz0b7TRijhbHvTsbzT6HL5u_TbLBbJatmWaU103DpDiwkZVH1uVUSgZ_EjBqpvTMFI2ZojFNZX7TM5Ps7ijb2-Js9KNZF8pJK6hSilcj9nTEYLR7CJBNcQF6B13I4AbTpfD_nR83A4GP</recordid><startdate>19960419</startdate><enddate>19960419</enddate><creator>Ezpeleta, Isabel</creator><creator>Irache, Juan M.</creator><creator>Stainmesse, Serge</creator><creator>Chabenat, Christiane</creator><creator>Gueguen, Jacques</creator><creator>Popineau, Yves</creator><creator>Orecchioni, Anne-Marie</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope></search><sort><creationdate>19960419</creationdate><title>Gliadin nanoparticles for the controlled release of all- trans-retinoic acid</title><author>Ezpeleta, Isabel ; Irache, Juan M. ; Stainmesse, Serge ; Chabenat, Christiane ; Gueguen, Jacques ; Popineau, Yves ; Orecchioni, Anne-Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-526c398248775aeee5678000484ee5e810d47522efec4f787b1c09abf2f134793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>All- trans-retinoic acid</topic><topic>Biological and medical sciences</topic><topic>Controlled release</topic><topic>Cross-linking</topic><topic>Desolvation</topic><topic>General pharmacology</topic><topic>Gliadin</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Nanoparticle</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ezpeleta, Isabel</creatorcontrib><creatorcontrib>Irache, Juan M.</creatorcontrib><creatorcontrib>Stainmesse, Serge</creatorcontrib><creatorcontrib>Chabenat, Christiane</creatorcontrib><creatorcontrib>Gueguen, Jacques</creatorcontrib><creatorcontrib>Popineau, Yves</creatorcontrib><creatorcontrib>Orecchioni, Anne-Marie</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ezpeleta, Isabel</au><au>Irache, Juan M.</au><au>Stainmesse, Serge</au><au>Chabenat, Christiane</au><au>Gueguen, Jacques</au><au>Popineau, Yves</au><au>Orecchioni, Anne-Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gliadin nanoparticles for the controlled release of all- trans-retinoic acid</atitle><jtitle>International journal of pharmaceutics</jtitle><date>1996-04-19</date><risdate>1996</risdate><volume>131</volume><issue>2</issue><spage>191</spage><epage>200</epage><pages>191-200</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The general objective of this work was to study the feasibility of preparing small-sized carriers from vegetal macromolecules. For this purpose, gliadin (a vegetal protein fraction from wheat gluten) nanoparticles were chosen as drug carriers for all-trans-retinoic acid (RA). The systems were prepared by a desolvation method for macro-molecules, which enabled us to obtain gliadin nanoparticles of about 500 nm, with a yield close to 90% of the initial protein. All experiments were performed using environmentally acceptable solvents such as ethanol and water. Moreover, due to the low solubility of this protein in water and to its high hydrophobicity, nanoparticles from gliadin do not need any further chemical or physical treatment to harden them. Gliadin nanoparticles were quite stable over 4 days in phosphate-buffered saline (PBS), but were degraded rapidly over 3 h when incubated in PBS solution containing trypsin. However, chemical cross-linkage of nanoparticles with glutaraldehyde significantly increased their stability. Under our experimental conditions, the payload limit was 76.4 μg RA/mg nanoparticles (for an RA/initial protein ratio of 90 μg/mg), which corresponded to a RA entrapment efficiency of about 75% of added drug. Nevertheless, the entrapment efficiency was high (between 97 and 85%) for RA/initial protein ratios up to 90 μg/mg. Finally, the in vitro release profiles of RA-loaded gliadin nanoparticles showed a biphasic pattern. An initial burst effect (in which about 20% RA was released) followed by zero-order diffusion (release rate 0.065 mg RA/h) were observed.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><doi>10.1016/0378-5173(95)04338-1</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 1996-04, Vol.131 (2), p.191-200
issn 0378-5173
1873-3476
language eng
recordid cdi_hal_primary_oai_HAL_hal_02699143v1
source Elsevier ScienceDirect Journals
subjects All- trans-retinoic acid
Biological and medical sciences
Controlled release
Cross-linking
Desolvation
General pharmacology
Gliadin
Life Sciences
Medical sciences
Nanoparticle
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
title Gliadin nanoparticles for the controlled release of all- trans-retinoic acid
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T05%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gliadin%20nanoparticles%20for%20the%20controlled%20release%20of%20all-%20trans-retinoic%20acid&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Ezpeleta,%20Isabel&rft.date=1996-04-19&rft.volume=131&rft.issue=2&rft.spage=191&rft.epage=200&rft.pages=191-200&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/0378-5173(95)04338-1&rft_dat=%3Celsevier_hal_p%3E0378517395043381%3C/elsevier_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=0378517395043381&rfr_iscdi=true